These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 16258082

  • 1. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
    Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD.
    J Clin Oncol; 2005 Nov 01; 23(31):7785-93. PubMed ID: 16258082
    [Abstract] [Full Text] [Related]

  • 2. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA.
    Clin Cancer Res; 2002 May 01; 8(5):1038-44. PubMed ID: 12006516
    [Abstract] [Full Text] [Related]

  • 3. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
    Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J.
    J Clin Oncol; 2005 Nov 01; 23(31):7794-803. PubMed ID: 16172456
    [Abstract] [Full Text] [Related]

  • 4. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
    Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ, Kris MG.
    J Clin Oncol; 2008 Feb 01; 26(4):639-43. PubMed ID: 18235124
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
    Mita AC, Olszanski AJ, Walovitch RC, Perez RP, MacKay K, Tuck DP, Simmons C, Hammond S, Mita MM, Beeram M, Stone AJ, Rowinsky EK, Lewis LD.
    Clin Cancer Res; 2007 Jun 01; 13(11):3293-301. PubMed ID: 17545535
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
    Mita M, Mita A, Sarantopoulos J, Takimoto CH, Rowinsky EK, Romero O, Angiuli P, Allievi C, Eisenfeld A, Verschraegen CF.
    Cancer Chemother Pharmacol; 2009 Jul 01; 64(2):287-95. PubMed ID: 19034451
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
    Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, Sikic BI.
    Clin Cancer Res; 2003 Nov 01; 9(14):5187-94. PubMed ID: 14613998
    [Abstract] [Full Text] [Related]

  • 8. [A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
    Teng XY, Guan ZZ, Yao ZW, Liu DG, Zhou NN, Luo HY, Hawkins M, Soon-Shiong P.
    Ai Zheng; 2004 Nov 01; 23(11 Suppl):1431-6. PubMed ID: 15566651
    [Abstract] [Full Text] [Related]

  • 9. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
    Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N.
    Clin Cancer Res; 2005 Jun 01; 11(11):4136-43. PubMed ID: 15930349
    [Abstract] [Full Text] [Related]

  • 10. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
    Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN.
    J Clin Oncol; 2005 Sep 01; 23(25):6019-26. PubMed ID: 16135470
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.
    Cancer Chemother Pharmacol; 2007 Jul 01; 60(2):203-9. PubMed ID: 17091249
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
    Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW.
    J Clin Oncol; 2008 Jan 20; 26(3):361-7. PubMed ID: 18202410
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
    Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH.
    Clin Cancer Res; 2005 Nov 01; 11(21):7834-40. PubMed ID: 16278406
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
    Nemunaitis J, Cunningham C, Senzer N, Gray M, Oldham F, Pippen J, Mennel R, Eisenfeld A.
    Cancer Invest; 2005 Nov 01; 23(8):671-6. PubMed ID: 16377585
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ.
    J Clin Oncol; 2003 Dec 01; 21(23):4428-38. PubMed ID: 14645433
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
    Soepenberg O, de Jonge MJ, Sparreboom A, de Bruin P, Eskens FA, de Heus G, Wanders J, Cheverton P, Ducharme MP, Verweij J.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):703-11. PubMed ID: 15701859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.